Company intelligence
Alzamend Neuro
Targeting treatment for Alzheimer's Disease, Major Depressive Disorder, Bipolar Disorder, and PTSD.
About Alzamend Neuro
Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.
Verified activity
Signals from Alzamend Neuro
4 published signals
Research & Knowledge
Alzamend Neuro is rediscovering Lithium's potential and learning how its innovative lithium reformulation could revolutionize treatment plans for Alzheimer's and beyond.
Reported by Alzamend Neuro
Presence & Recognition
Alzamend Neuro CEO Stephan Jackman sat down with BioPharmCatalyst | A Scientist.com Company's John Gagliano to discuss improving Alzheimer's treatments with safer, more targeted approaches including a next-generation lithium and an autologous immunotherapeutic vaccine.
Reported by Alzamend Neuro
Research & Knowledge
Alzamend Neuro announced that its lead product candidate AL001 uses proprietary ionic cocrystal technology to deliver a therapeutic combination of lithium, proline, and salicylate.
Reported by Alzamend Neuro